We report the generation and use of pseudotyped adeno -associated viral (AAV) vectors for the liver-specific expression of human blood coagulation Factor IX (hFIX). Therefore, an AAV-2 genome encoding the hfIX gene was crosspackaged into capsids of AAV types 1 to 6, using efficient large-scale technology for particle production and purification. In immunocompetent mice, the resulting vector particles expressed high hFIX levels ranging from 36% (AAV-4) to over 2000% of normal (AAV-1, -2 and -6), which would exceed curative levels in hemophilic humans. Expression was dose-and time-dependent, with AAV-6 directing the fastest and strongest onset of hFIX expression at all doses.
Introduction
Hemophilia B is the clinical manifestation of an inherited deficiency or defect in human blood coagulation Factor IX (hFIX), resulting in spontaneous soft tissue and joint bleeding episodes, most severely pronounced in patients having less than 1% of the normal circulating hFIX level (5 µg/ml). The clinical endpoints of hemophilia treatment are well defined : an increase in hFIX levels up to 5 % of normal (therapeutic range) will improve the disease phenotype from severe to moderate, and greater levels (curative range) will result in a mild phenotype.
These low threshholds make the disease one of the most promising candidates for eventual cure with somatic gene therapy, 1 where the aim is to introduce a functional hfIX gene into the hemophilic patient, to provide sustained expression of clotting factor in the circulation. To develop a gene therapy for hemophilia B has been the focus of intense efforts, and a wide variety of strategies have been evalu ated in murine and canine models over the last decade . Generally, the y differed in the promoters (ubiquitous or tissue-specific) driving expression of the hfIX gene, the tissues specifically targeted (liver, muscle or lung), and the vector (non-viral or viral) used to deliver the hfIX expression cassette.
e.g., [2] [3] [4] Of the combinations tried so far, those involving vectors derived from adenoassociated virus type 2 (AAV-2), a single-stranded, human DNA parvovirus, hold particular promise. This vector system provides numerous advantages over other viral vector candidates, 5 including the ability to direct long-term gene expression from integrated or episomal forms of the viral genome, a lack of toxicity or pathogenicity associated with the wildtype virus and vectors derived thereof, and the feasibility to produce AAV-2 vector particles at high titer and purity. 6 Preclinical analyses of AAV-2 vectors in the context of hemophilia B have thus far yielded encouraging results, with the most remarkable reports demonstrating expression of curative hFIX levels in hemophilic mice and dogs for more than 17 months. 2, 7 Moreover, ongoing phase I clinical trials of muscle-or liver-directed gene transfer with hFIX-expressing AAV-2 vectors so far show that the recombinant particles are well-tolerated. 8, 9 Despite these promising results, two major drawbacks warrant further development of this system : firstly, the efficiency of in vivo liver transduction with AAV-2 is low, due to a limited subpopulation of hepatocytes that is susceptible to AAV-2 infection at a time, 10 and secondly, the high prevalence of neutralizing antibodies against AAV-2 in the population e.g., 11 is likely to hamper AAV-2 vector-mediated gene transfer in a large number of patients.
Alternative serotypes of AAV represent vectors which could circumvent these drawbacks. Seven other serotypes have thus far been described, denoted AAV-1 to AAV-8, with AAV-6 likely representing a hybrid between AAV-1 and AAV-2. ), but reports of AAV serotype transduction of the liver have so far been limited and inconsistent. 11, 19, 20 In view of these limitations, we aimed to provide a thorough side-by-side comparison of AAV serotype vectors for liver-directed gene transfer, including all serotypes that were available 4 at the time of our study, i.e., AAV-1 to AAV-6. We developed tools and technology that allowed us to cross-package an AAV-2 vector genome, containing our most robust hfIX expression cassette, into capsids derived from AAV-1 to -6. These pseudotyped AAV vectors were then evaluated in immunocompetent mice for their ability to express hFIX protein. Expression depended on a) the vector serotype, b) the virus particle dose, c) the time after vector injection, and d) the route of particle administration. We also show that the different AAV pseudotypes varied in tissue distribution of the vector genomes, and in their ability to generate (cross-)neutralizing antibodies. The large-scale production technology, together with the results and conclusions reported here should further improve the prospects of AAV-mediated gene therapy for liver diseases, such as hemophilia B.
Methods

Plasmids
The AAV-2 vector plasmid phF.IX-16 has been described. 3 Briefly, this construct contains the apolipoprotein E hepatic locus control region (ApoEHCR)-human 1-antitrypsin promoter (hAAT)-driven hfIX minigene (including the 1.4 kb intron A) and a bovine growth hormone polyadenylation signal, flanked by inverted terminal repeats of AAV-2. The adenoviral helper plasmid pladeno5, used for helpervirus-free AAV vector production (see below), has also been described. 21 A second helper expressing AAV-2 Rep and capsid (VP) proteins, pHLP19-2, was constructed by subcloning AAV-2 nucleotides 315 to 4534 from pSM620 22 into pBluescript s/k+ (Stratagene, LaJolla, California, USA). The AAV-2 p5 promoter was moved to a position 3' of the AAV polyadenylation site, and was replaced by a 5' untranslated region primarily composed of a FLP recombinase recognition sequence (frt). Additionally, the seven base pair TATA box of the p5 promoter was destroyed by mutation to GGGGGGG ( Figure 1A ).
Initially part of efforts to generate an inducible AAV-2 expression construct, these modifications were found to result in enhanced AAV vector yields, and to suppress the generation of replication competent pseudo-wildtype virus.
Chimeric helper plasmids encoding the AAV-2 rep gene and capsid genes from AAV types 1 or 3B to 6 were derived from pHLP19-2 and named pHLP19-1 and pHLP19-3 through -6, respectively. The first chimeric construct, pHLP19-6, Prior to ligation, the PCR fragments were digested with AgeI, and the AAV-1 and -5 fragments were also digested with SwaI. All PCR reactions were performed using Pfu DNA polymerase (Stratagene, La Jolla, California, USA).
The integrity of all five chimeric helpers was verified by sequencing the cap regions.
Vector Production
Vented vector plasmid and the two helpers (pladeno5 and one of the pHLP19 plasmids) was rapidly mixed with 10 ml of 2xHBS (50 mM HEPES, 280 mM NaCl, 1.5 mM Consequently, cultures involving AAV-3 to -6 helpers produce roughly twice as much total vector particles as compared to AAV-2.
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Vector Purification
The RNase A (2 ml per roller bottle) and applied to a CsCl step gradient, consisting of 5 ml 1.5 g CsCl/ml for the bottom layer, 10 ml 1.3 g CsCl/ml for the middle layer, 
Analysis of vector transduction in vitro and in vivo
In vitro transduction activities of the vectors were assessed by infecting For assessment of in vivo transduction, vectors were infused as previously described 24 into the portal or tail vein of 6 week old C57Bl/6 mice (Jackson Laboratories, Bar Harbour, Maine, USA) at the particle doses specified in the text. At various timepoints after vector infusion, blood was collected from the animals by retro-orbital plexus bleed, and hFIX levels in the plasma were determined by hFIX ELISA.
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Analyses of vector integrity
SDS-PAGE analysis was performed according to the manufacturer's instructions (Invitrogen, Carlsbad, California, USA), using 8x6x0.1 cm, 10%
acrylamide gels, and proteins were visualized by silver staining (Daiichi, Tokyo, Japan). Dynamic light scattering analysis was performed using a Protein Solutions, DynaPro model according to the manufacturer's recommendations (Charlottesville, Virginia, USA). Analysis of 1x10 10 to 1x10 11 particles in a volume of 12 µl showed hydrodynamic radii of 12 nm for 100% of the vectors in each preparation, indicating that the particles were monomeric and not aggregated.
Vector DNA tissue distribution analyses
Mice were sacrificed 6 weeks after portal or tail vein injection of 2x10 After 16 hours of incubation at 37°C with 5% CO 2 , the medium was replaced with 400 µl fresh DMEM, and the cells were further incubated for 5 days, before, the amount of hFIX protein in the media was determined by hFIX ELISA. 23 For each sera and AAV type, a titer of (cross-)neutralizing antibodies was calculated as the reciprocal of the highest dilution of the sera, that inhibited transduction of the particles by at least 50% of that from the corresponding negative controls. To assess functionality of the particles in vitro, we infected HepG2 cells with increasing multiplicities of infection from 333 to 3.3x10 6 , under conditions described in Methods. Human FIX levels in media harvested 24 hours after infection were measured by ELISA ( Figure 1C ). All six vectors expressed hFIX, and vectors derived from AAV-2 to -6 responded rather similarly to increasing dose, reaching a plateau of hFIX expression at the second highest dose.
Interestingly, the AAV-6 vector produced greater responses at the lower doses, and overall, the AAV-1 vector transduced the cells less efficiently than the other five serotypes.
In vivo expression of human Factor IX from AAV serotype vectors
To determine the efficiency of pseudotyped AAV vector-mediated transduction of hepatocytes in vivo, we injected C57Bl/6 mice with "low" (2x10 Human FIX levels above the curative threshold were also found after portal vein delivery of the middle particle dose for all vectors, with the exception of AAV-4, which only expressed at the highest dose. Portal vein administration of the low dose resulted in expression from three of the six serotypes, with hFIX levels above the therapeutic (AAV-3) or curative (AAV-2 and -6) threshold.
Tail vein delivery of the high dose gave hFIX levels in the curative range from all six serotypes, whereas at the middle dose, only the three overall strongest expressing AAV types, 1, 2 and 6, resulted in curative hFIX levels. AAV-3 expressed close to the therapeutic threshold and expression from AAV-4 and -5 was undetectable. Human FIX levels were also undetectable from all vectors after tail vein delivery of the low dose.
In most cases, portal vein particle infusion resulted in much stronger hFIX expression than tail vein delivery of the same vector dose, as most obvious from the 84-fold difference seen after injection of the middle dose of AAV-3.
Surprisingly however, at the high dose, AAV types 1, 4 and 6 expressed almost equally efficiently from both routes of administration.
Dose-response and kinetics of AAV serotype vector-mediated gene expression
Despite the greater than 99% sequence homology between AAV-1 and AAV-6, 12 we found that AAV-6 mediated consistently higher levels of hFIX expression than AAV-1 and expressed the transgene with faster kinetics (see Figure 2 ). To confirm this finding, we injected new mice via the portal vein with the three most strongly expressing AAV pseudotypes (1, 2 and 6), at nine different doses which increased in two-fold increments from 1.56x10 9 to 4x10 11 particles per mouse.
Expression of hFIX protein was monitored starting 3 days after particle injection, and then at days 7, 14, and 42, when hFIX levels were expected to be stable (see Figure 2) . As evident from the expression kinetics ( Figure 3A,B) , and the quantitative comparison of hFIX expression ( Figure 3C ), there were indeed significant differences in dose-response and kinetics between all three AAV vector s. While all serotypes exhibited an approximately linear dose-response, the AAV-6 vector gave strongest expression at all doses tested ( Figure 3A) , and reached a plateau of maximal expression at earlier timepoints ( Figure 3B ). The faster onset of expression was striking at day 3 after injection, where AAV-6 expressed at two lower doses than AAV-1 and -2, and yielded up to greater than one hundred-fold more hFIX protein at higher doses ( Figure 3A , top). At this early timepoint, 5x10 10 particles of AAV-6 were already sufficient to reach potentially curative hFIX levels, whereas four-fold higher doses of AAV-1 or -2 were required to achieve similar levels. At later timepoints, AAV-6 consistently expressed hFIX from lower doses than AAV-1 or -2 ( Figure 3A ).
Although both AAV-1 and -2 expressed hFIX less efficiently than AAV-6 at earlier timepoints, the expression profile of AAV-2 shifted over time from being identical to AAV-1 to more closely matching the profile of AAV-6 ( Figure 3A ,C).
AAV-1 remained less efficient than AAV types 2 and 6, except at the highest dose (4x10 11 vg), at which all three vectors expressed with similar efficiency.
These data demonstrate that all three AAV serotypes have distinct expression kinetics, and further support that AAV-1 and -6 are distinct members of the AAV family, despite their extensive homology.
Tissue distribution of AAV serotype vector DNA
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The promoter used to drive expression of the hfIX gene in all six AAV vectors was liver-specific, implying that the plasma hFIX protein detected originated in the livers of the mice. To confirm that AAV vector copy numbers in the livers corroborated protein levels, and to analyse whether vector DNA was also present in other tissues, we extracted genomic DNA from liver, heart, kidney, spleen, brain and lung, from mice sacrificed 6 weeks after portal or tail vein injection with middle vector doses of each serotype. Human fIX vector genomes were quantified in identical amounts of genomic DNA using Southern Blotting (livers only, a representative blot is shown in Figure 4A ) and Q-PCR (all tissues, Figure   4B ). In all samples, the liver vector genome numbers correlated with the plasma levels of hFIX protein ( Table 1 ). The ratios of plasma hFIX levels to liver genome copy numbers were consistent between the groups, only the AAV-3 vector gave slightly higher ratios, indicating that for reasons unknown, relative protein expression per genome was stronger for AAV-3. When comparing the ratios of liver DNA copy numbers between portal and tail vein injected mice, we noted a good correlation to the ratios of the plasma hFIX protein levels for AAV serotypes 1 to 3 and 6. For AAV-4 and -5, this correlation was not evident due to the low hFIX expression, although the equal numbers of vector genomes found after portal or tail vein delivery of AAV-4 were reminiscent of the similar protein levels seen at the high dose of this vector (Figure 2 ). AAV genomes were detected in livers from vector-treated animals, and quantified using Southern Blotting or quantitative PCR (Q-PCR) as described in Methods. Shown are absolute (Southern Blot) or relative (Q-PCR) genome copy numbers per cell, together with hFIX levels expressed (means with standard deviation (SD), n = 3 per group). Within the Q-PCR data, values obtained from AAV-6 portal vein-injected animals served as an internal reference and were set to 1, due to lack of an appropriate absolute standard (see Methods). Also shown are ratios of copy numbers or hFIX levels after portal or tail vein delivery of each vector (pv:tv). The rightmost column lists ratios of hFIX levels to relative genome copy numbers.
AAV-1(TV) AAV-2(PV) AAV-2(TV) AAV-3(PV) AAV-3(TV) AAV-4(PV) AAV-4(TV) AAV-5(PV) AAV-5(TV) AAV-6(PV) AAV-6(TV)
A Below detection limit of the method. nd, not detected; pv, portal vein; tv, tail vein.
Emergence of cross-neutralizing antibodies from AAV serotype vector delivery
To determine whether the mice had generated neutralizing antibodies against the different vectors, and whether these would cross-react amongst the AAV type s, w e performed a virus neutralization assay (see Methods), using sera from the same animals analysed in the tissue distribution study.
As summarized in Table 2 , delivery of each AAV vector yielded the expected neutralizing antibodies against the same AAV type (grey boxes). This was most pronounced for AAV-4, which after portal or tail vein injection elicited high titers of neutralizing antibodies above the detection limit of our assay. AAV-4 was also the only serotype that was not neutralized by antibodies against other serotypes.
The opposite was observed for AAV-5, which generated only low levels of selfneutralizing antibodies, but was inhibited by antibodies against all other types, with the exception of AAV-4.
Cross-reactivity between AAV serotypes was noted in 12 cases, and usually resulted in moderate titers of neutralizing antibodies. An interesting exception were the AAV-1 and -6 vectors, each of which yielded antibodies which efficiently cross-neutralized the other AAV type. This supports the notion that AAV-1 and -6 are closely related serotypes.
Noteworthy was that in 14 of the 18 total cases of antibody emergence, systemic particle injection led to a stronger immune response against the same or other AAV types, than direct hepatic delivery. This generally suggested that the hepatic route of particle administration is favorable for liver-directed gene transfer strategies which rely upon re-administration of AAV serotype vectors. Four-fold serial dilutions of sera from mice injected with recombinant AAV serotypes 1 to 6 were incubated with the same viruses in all possible combinations, and residual virus infectivity was determined (see Methods for details). Three independent samples were analysed per group. Grey boxes highlight titers of neutralizing antibodies against the same serotype that the mice were initially injected with. A Antibody titers are given as reciprocals of the highest sera dilutions that caused a decrease in vector infectivity of at least 50%.
B pv, portal vein; tv, tail vein. nd, not detected.
Discussion
The present work was inspired by recent reports demonstrating that vectors based on AAV serotypes differ in cell tropism and serology from the commonly used AAV vector type 2 (reviewed in 18 ). This suggests they can be used to target tissues that are resistant to efficient infection with AAV-2, or to circumvent To address these issues accurately, we aimed to ensure that differences between the vectors were limited to the particle capsids which originated from the different AAV types. This was achieved by pseudotyping the identical hfIXexpressing AAV-2 vector DNA with the six different AAV capsids, using the same large-scale plasmid transfection protocol. The resulting particles were purified and concentrated by an identical CsCl-based procedure, which further ensured that the six preparations were comparable. Importantly, the high degree of particle purity achieved, together with the high particle yields obtainable from transfected cells in roller bottles, makes the technology presented here appealing for clinical-grade vector production.
We found that all six AAV vectors were able to direct high-level hFIX expression from the liver, yielding maximum levels ranging from 36% to greater than 2700% of normal, which is in great excess of the curative threshold for hemophilic humans. With a peak of 134.9 µg/ml (AAV-6), our hFIX levels were also in excess of previously reported levels from any viral or non-viral vector systems. This was likely due to the conditions for efficient hepatocyte transduction used here, i.e., direct hepatic infusion of high vector doses and a strong liver-specific enhancer/promoter driving hfIX expression, but it also clearly highlights the great potential of AAV serotypes for liver-directed gene delivery.
Our finding is clinically relevant, considering that anti-AAV-2 antibodies prevalent in the population might prevent a substantial number of subjects from efficient treatment with the AAV-2 vector system. 11, 12 For these individuals, hepatic gene delivery could be achieved by simply pseudotyping a therapeutic gene with an alternative AAV shell, to which the patient is not already immune. In this respect, it is interesting to note that Gao and coworkers 11 recently described successful hepatic gene transfer with two further serotypes, AAV-7 and -8, thus extending the number of AAV serotypes to target the human liver to eight.
Importantly, antibodies against most AAV serotypes other than 2 appear to be rare in the human population. 11, 12, 25 In our hands, none of the alternative serotypes expressed significantly more strongly in the liver than the AAV-2 vector. Mingozzi et al . 20 reported up to 25-fold 28 higher efficiency from AAV-5 in the murine liver, and Rabinowitz et al. 19 likewise
claimed that serotypes 1, 3 and 5 worked better in liver than AAV-2. In contrast,
we found that maximal expression from AAV-1 was comparable to the AAV-2 vector, and our most efficient vector, AAV-6, gave only 1.3-fold higher hFIX levels than AAV-2. Only about 50% of the maximum hFIX protein level from AAV-2 was obtained from the AAV-5 vector. While this is difficult to reconcile with published results, the discrepancies may be due to a number of issues. For instance, in one recent study, the AAV-2 vector was purified using a different method from the other vector pseudotypes. 11 These authors reported that pseudotypes 1, 5 and 8 outperformed serotype 2, with AAV-8 transducing up to 110-fold more efficiently, but the inconsistencies between vector preparation, coupled with the finding of dramatically lower AAV-2 vector genomes in the liver than reported by others, e.g., 10 raises doubts as to the validity of such comparisons. Moreover, as exemplified by the faster kinetics of expression from AAV-6, we showed that the transduction profile of different AAV serotypes is dependent upon virus dose, and upon the timepoint which is examined.
Differences in expression kinetics and doses administered could further explain some of the disagreements with previous reports, where only one vector dose and timepoint after virus administration was investigated. 19 The finding of unique dose-responses and expression kinetics for different AAV serotypes is of interest, not only as it provides novel insight into virus biology, but also because it implies that lower particle doses could be used to achieve therapeutic protein levels, and/or these levels could be reached earlier after vector administration. From a clinical standpoint, both would be highly desirable, since lower vector doses provoke a reduced antibody response and save cost and time for vector preparation, and faster transgene expression translates into a shortened lag phase to reach therapeutic protein levels.
Our findings that the AAV-6 vector expressed stronger and with faster kinetics than comparable doses of the other vector serotypes is consistent with our previous observations of faster expression kinetics for AAV-6 vectors in various cultured cells, 26 and was also found here in a human liver cell line. The fact that the vector DNA was in all cases identical between the serotypes, suggests that AAV-6 is faster in early steps of cell entry, such as receptor binding, and/or intracellular events following virus uptake. As this requires further exploration, it is noteworthy that these kinetics were not observed for AAV-1, although the capsid proteins of AAV-1 and -6 differ in only six amino acids, 12 providing a good basis for future investigation.
Our comparison of the hepatic and systemic routes for particle administration indicated another potential benefit of AAV serotype vectors. For AAV-2, hFIX levels after direct hepatic delivery were at least 3-fold higher than those from systemic delivery of the same particle dose, corroborated by increased numbers of liver vector genomes. This is consistent with previous reports from our group and others, 20, 24 and similar results were also found here for all other serotypes after injection of low or moderate doses. Interestingly however, at the high dose (2x10 12 particles) of AAV types 1, 4, and 6, hFIX protein levels were nearly identical by the hepatic and systemic route, while the protein levels were still significantly different for the other serotypes at this dose. The feasibility of expressing hFIX from intravenous injection at levels equal to those from intrahepatic infusion is very attractive for the clinic, due to the minimal invasiveness of the process, as compared to the surgical procedure needed to access the portal vein. A drawback may be that systemic application yielded increased titers of antibodies neutralizing the viral capsids, which might prevent repeated vector delivery. Thus, additional studies are required to fully evaluate the advantages and disadvantages of either route of vector particle administration.
It will also be of interest to delineate the molecular basis for the differences in protein expression between the AAV serotypes following hepatic or systemic delivery. One explanation is that when delivered systemically, AAV-2 becomes sequestered in extracellular heparan sulfate proteoglycans (HSPG), which serve as the primary receptor for AAV-2, 27 resulting in reduced vector diffusion and transduction capabilities. This may not affect AAV-1 and -6; although the putative receptors remain unknown, our findings indicate that they are not extracellularly abundant. HSPG may also not affect AAV-4, which requires 2-3 O-linked sialic acid and possibly other membrane-bound determinants for efficient infection. 28 In this respect, it was interesting to obtain evidence for an AAV-4 lung tropism in our vector tissue distribution analyses, since 2-3 O-linked sialic acid is present on human airway epithelia cells, but mucins prevent the virus from infecting the cells from the apical surface. 29 Thus, systemic administration might provide an intriguing alternative means of AAV-4 vector-mediated gene delivery to the lung.
In summary, our study yielded strong evidence that vectors based on AAV serotypes might offer three important benefits for clinical liver-directed gene transfer : the ability 1) to express a transgene faster and from lower vector doses, 2) to obtain therapeutic expression through a non-invasive, systemic route of administration and 3) to circumvent pre-existing immunity in patients with circulating anti-AAV neutralizing antibodies. The latter might also allow for vector re-administration, which particularly in the liver might yield an additive effect, since only a subpopulation of hepatocytes are susceptible to infection at a time. 10 In this respect, promising candidates worth testing are AAV types 1 to 3, which yielded no or low levels of cross-reacting antibodies, and in particular AAV-4, which did not cross-react with any other AAV type. Finally, co-administration of vector pseudotypes may increase the total number of hepatocytes transduced.
Mingozzi et al. 20 recently investigated this approach with capsids of AAV-2 and -5
and observed widely overlapping populations of cells in the murine liver, however, results may be different with other combinations of serotypes, or in human liver.
The development of vectors allowing for the efficient transfer of the human fIX gene to the liver remains a crucial goal for the eventual cure of hemophilia B. Our study has provided compelling evidence that serotypes of AAV could provide a solid basis for such vectors, as they offer many advantages over the established AAV-2 vector system. It will be exciting to extend their analysis to larger animal models, which should help delineate the exact parameters required for optimum Depicted also is the mutation of the p5 TATA box, from the genuine sequence as present in wildtype AAV-2 plasmid pSM620 (top) to a modified sequence (below). C57Bl/6 mice (n = 5 or 8) were injected with AAV serotype 1 to 6 vectors expressing the human factor IX gene, at three different particle doses, i.e. 2x10 10 (low dose, "l"), 2x10 11 (middle dose, "m"), or 2x10 12 (high dose, "h") genomecontaining particles. Vectors were injected through the portal vein ("pv") or the tail vein ("tv"). Shown are plasma levels (mean ± SD) of Factor IX protein measured between day 3 after particle injection up to day 84, by ELISA. The lines in each graph indicate 1% of normal FIX levels (solid line), 5% (dotted line), or 100%
(dashed line). A hFIX plasma level of 5 ng/ml was considered as the detection limit of the assay, protein levels below this limit are thus not shown. 
